EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.

View source ↗

Summary

The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, precursor cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Ovarian Neoplasms
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Phelinun (melphalan hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma;Hodgkin Disease;Lymphoma, Non-Hodgkin;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myeloid, Acute;Neuroblastoma;Ovarian Neoplasms;Hematopoietic Stem Cell Transplantation. MAH: ADIENNE S.r.l. S.U.. Decision date: 22/05/2025